EADV 2024 | BADBIR 研究 36 个月结果出炉,依奇珠单抗维持长期应答和药物留存

文摘   2024-11-11 20:01   上海  


本文仅供中国大陆地区执业的医学药学专业人士参考,如您非前述专业人士,请离开本页面




✩ 本文仅供医疗卫生等专业人士参考


*此文仅用于向医疗卫生专业人士提供科学信息,不代表平台立场


审批编码:PP-IX-CN-4788

获批日期:2024 年 10 月 21 日


内容策划:钱程
项目审核:曹欢
题图来源:丁香园自制  


参考文献

[1] Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020 May;13(5):493-503.

[2] Savage L, Hughes J, Casey C, et al. Thirty-six-month follow up of ixekizumab in the BADBIR registry: baseline demographics, drug survival and effectiveness in biologic-naïve versus biologic-experienced patients with psoriasis. 2024 EADV. Poster P3335 & Abstract 5824.

[3] Savage L, Hughes J, Casey C, et al. Thirty-six-month follow-up of ixekizumab in psoriasis patients with and without the involvement of high impact areas (nail, scalp, palmoplantar or PsA): data from the BADBIR registry. 2024 EADV. Poster P3337 & Abstract 5902.

[4] Christopher E. M Griffiths, et al. AAD 2022.32236.


丁香园皮肤时间
丁香园旗下公众号,更懂中国皮肤科医生。前沿、用药、指南、病例一网打尽,轻松玩转皮肤科。
 最新文章